Scholarlink

<p>A pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with favorable outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer; however, brain metastases still occur. Using the National Clinical Database–Breast Cancer Registry (JAPAN 2008–2020), we identified 21,494 patients who received NAC followed by surgery. After excluding cases without pCR status or prognostic data, 8421 patients were analyzed (2430 pCR; 5991 non-pCR). Disease-free survival (DFS), brain metastasis-free survival, and recurrence patterns were compared, and risk factors for distant recurrence were evaluated. Patients achieving pCR had significantly better 5-year DFS than non-pCR patients. Among pCR cases, hormone receptor status and clinical stage independently predicted recurrence. At 5 years, brain metastases occurred in 2.6% of pCR patients and 4.5% of non-pCR patients. These findings indicate that pCR does not eliminate the risk of brain metastases, highlighting the need for continued vigilance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Mayako Terao,
  • Hiraku Kumamaru,
  • Naoko Kinukawa,
  • Toru Hanamura,
  • Yasuaki Sagara,
  • Takayuki Iwamoto,
  • Minoru Miyashita,
  • Takanori Ishida,
  • Naruto Taira,
  • Shigehira Saji,
  • Naoki Niikura

摘要

A pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with favorable outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer; however, brain metastases still occur. Using the National Clinical Database–Breast Cancer Registry (JAPAN 2008–2020), we identified 21,494 patients who received NAC followed by surgery. After excluding cases without pCR status or prognostic data, 8421 patients were analyzed (2430 pCR; 5991 non-pCR). Disease-free survival (DFS), brain metastasis-free survival, and recurrence patterns were compared, and risk factors for distant recurrence were evaluated. Patients achieving pCR had significantly better 5-year DFS than non-pCR patients. Among pCR cases, hormone receptor status and clinical stage independently predicted recurrence. At 5 years, brain metastases occurred in 2.6% of pCR patients and 4.5% of non-pCR patients. These findings indicate that pCR does not eliminate the risk of brain metastases, highlighting the need for continued vigilance.